(NASDAQ: KURA) Kura Oncology's forecast annual revenue growth rate of 21.32% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 102.3%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.86%.
Kura Oncology's revenue in 2025 is $104,029,000.On average, 17 Wall Street analysts forecast KURA's revenue for 2025 to be $11,166,958,085, with the lowest KURA revenue forecast at $2,302,483,526, and the highest KURA revenue forecast at $20,750,197,342. On average, 17 Wall Street analysts forecast KURA's revenue for 2026 to be $18,689,622,516, with the lowest KURA revenue forecast at $5,261,601,243, and the highest KURA revenue forecast at $41,225,419,328.
In 2027, KURA is forecast to generate $13,725,273,114 in revenue, with the lowest revenue forecast at $4,530,741,110 and the highest revenue forecast at $29,694,728,018.